Vitamin a derivative patch could reverse oral precancer

NCT ID NCT07149220

Ongoing Disease control Sponsor: Ohio State University Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a sticky patch that releases fenretinide, a vitamin A derivative, directly onto precancerous spots inside the mouth. The goal is to see if the patch can shrink these lesions, reduce their severity under the microscope, and lower genetic changes linked to oral cancer. The study involves healthy volunteers and people with confirmed oral precancer, who apply the patch twice daily for six weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fenretinide mucoadhesive system
What this could lead to: If effective, this patch could offer a non-surgical way to reverse precancerous mouth lesions and lower the risk of oral cancer.
What could go wrong: This is a small early-phase trial, so results may not confirm effectiveness. The patch may cause irritation or fail to shrink lesions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ORAL DYSPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intraepithelial neoplasia oral mucosa leukoplakia lip and oral cavity carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ORAL DYSPLASIA ORAL LEUKOPLAKIA

Contacts and locations

Locations

Ohio State University College of Dentistry

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.